Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given a consensus rating of “Buy” by the nine analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $35.86.

Several equities analysts recently commented on DAWN shares. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Bank of America reduced their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $12.24 on Friday. The company has a market cap of $1.23 billion, a PE ratio of -11.88 and a beta of -1.46. Day One Biopharmaceuticals has a 1 year low of $11.13 and a 1 year high of $18.07. The stock’s 50 day simple moving average is $12.94 and its two-hundred day simple moving average is $13.89.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the previous year, the company posted ($0.54) EPS. Equities research analysts expect that Day One Biopharmaceuticals will post -0.85 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 51,745 shares of company stock valued at $748,567. 8.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares in the last quarter. SteelPeak Wealth LLC boosted its stake in Day One Biopharmaceuticals by 9.8% in the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after acquiring an additional 1,550 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Day One Biopharmaceuticals by 16.9% in the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after acquiring an additional 3,900 shares in the last quarter. Martingale Asset Management L P boosted its stake in Day One Biopharmaceuticals by 9.6% in the third quarter. Martingale Asset Management L P now owns 71,304 shares of the company’s stock valued at $993,000 after acquiring an additional 6,219 shares in the last quarter. Finally, Verition Fund Management LLC boosted its stake in Day One Biopharmaceuticals by 31.4% in the third quarter. Verition Fund Management LLC now owns 31,075 shares of the company’s stock valued at $433,000 after acquiring an additional 7,422 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.